Group 1 - The company's stock (Galaxy Electronics, stock code: 002519) experienced an abnormal trading fluctuation, with a cumulative closing price drop exceeding 20% over three consecutive trading days from January 15 to January 19, 2026 [1] - The board of directors confirmed that there are no undisclosed significant matters or other major issues under planning that should be disclosed according to the Shenzhen Stock Exchange regulations [1][2] - The company has not identified any need to correct or supplement previously disclosed information, and its production and operations remain normal without any expected significant changes [1][2] Group 2 - The board of directors has confirmed that there are no undisclosed matters that could significantly impact the company's stock price, and all prior disclosures are accurate [2] - The company’s controlling shareholder, Galaxy Electronics Group Co., Ltd., did not engage in buying or selling the company's stock during the period of abnormal trading fluctuations [1]

Core Viewpoint - The company, Bluestar Medical Co., Ltd., has received EU CE certification for its LithonicTM Coronary Intravascular Lithotripsy system, marking a significant advancement in the treatment of calcified lesions in coronary arteries [1][2]. Group 1: Product Information - Product Name: LithonicTM Coronary Intravascular Lithotripsy (IVL) Catheter / Generator [1] - Manufacturer: Biosensors Interventional Technologies Pte. Ltd. (Singapore) [1] - Validity Period: Until January 13, 2031 [1]. Group 2: Product Description - The LithonicTM system utilizes high-pressure sound waves to treat severely calcified narrow areas in blood vessels, particularly where balloon dilation or stent expansion is ineffective [1]. - The system operates on the principle of electrolysis in an electrolyte solution, allowing precise release of high-pressure shock waves to modify calcified lesions and reduce complications associated with traditional treatment methods [1]. Group 3: Impact on the Company - The IVL technology is emerging as a preferred clinical option for treating calcified lesions due to its unique mechanism of action [2]. - The CE certification enhances the company's technological leadership in the coronary field and is expected to positively impact the company's operational development and overall competitiveness in the cardiovascular sector [2].

Group 1 - The company Zhejiang Weigang Technology Co., Ltd. received a notification from its controlling shareholder, Zhejiang Chengwei Equity Investment Co., Ltd., regarding changes in its business registration information, including name, registered capital, and business scope [1] - The registered capital of Wenzhou Chengwei Venture Investment Co., Ltd. is proposed to be reduced to 26,000,000 yuan, with the remaining changes not yet completed [1] - The changes in the business license do not affect the shareholding structure of the company, and there are no changes in the controlling shareholder or actual controller, thus having no impact on corporate governance or business operations [1] Group 2 - The updated business license information includes the address located in Pingyang County, Wenzhou City, and the business scope which includes venture capital limited to investing in unlisted companies and conducting investment activities with its own funds [1] - The company was established on October 16, 2020, with a registered capital of 26,058,400 yuan and is classified as a limited liability company [3] - The legal representative of the company is Li Yuhua [3]

Core Viewpoint - Shenzhen Suoling Industrial Co., Ltd. has completed the registration changes and amendments to its articles of association as approved in recent board and shareholder meetings [1][2]. Group 1: Company Actions - The company held the 25th meeting of the fifth board of directors and the second extraordinary general meeting of shareholders on December 8 and December 29, 2025, respectively, to approve various proposals [1]. - The approved proposals included changes to the company's registered capital, amendments to the articles of association, and the election of non-independent and independent directors for the sixth board of directors [1]. - On January 16, 2026, the company completed the industrial and commercial registration changes and the filing of the amended articles of association, receiving a registration notice from the Shenzhen Market Supervision Administration [1]. Group 2: Documentation and Disclosure - The company disclosed the resolutions from the board meeting and the extraordinary general meeting in various financial newspapers and on the official website [1]. - The articles of association filed with the industrial and commercial bureau remain unchanged except for the aforementioned modifications [1].

Core Viewpoint - The company is set to release 14,457,831 shares from lock-up, representing 0.6846% of its total shares, with the release date scheduled for January 22, 2026 [1][2]. Group 1: Basic Information on Share Release - The release of locked shares is approved by the China Securities Regulatory Commission, following the acquisition of a 95.77% stake in Wanda Film Media Co., Ltd. through the issuance of 316,985,827 shares [1]. - The shares were originally issued to various parties, including 14,457,831 shares to Ms. Lin Ning, and were listed on May 27, 2019 [1]. Group 2: Shareholder Commitment and Compliance - The shareholders involved in the release have fulfilled their performance commitments, with a total of 162,700,446 shares repurchased and canceled by the company due to unmet performance targets for the years 2019, 2021, and 2022 [2]. - As of the announcement date, there are no outstanding commitments that would affect the release of the locked shares [2]. Group 3: Listing and Structural Changes - The listing date for the released shares is confirmed as January 22, 2026, with a total of 14,457,831 shares being released [2][3]. - The company confirms that there are no non-operational fund occupations or violations of commitments by the shareholders involved in the release [2][3]. Group 4: Independent Financial Advisor's Opinion - The independent financial advisor, China International Capital Corporation, has verified that the release of the locked shares complies with relevant laws and regulations, and there are no violations of commitments by the shareholders [3].

Group 1 - The core point of the announcement is that the actual controller of Huabang Life Health Co., Ltd., Mr. Zhang Songshan, has notified the company about the release of a portion of his pledged shares [1] - The announcement includes details about the basic situation of the release of the pledge and the cumulative pledge situation of Mr. Zhang Songshan and his concerted actors [1] - As of the date of the announcement, the pledged shares held by Mr. Zhang Songshan and his concerted actors, including Chongqing Huibang Zhuoyuan Technology Co., Ltd., Zhang Yizhuo, and Zhao Danlin, are specified [1]

Group 1 - The company plans to amend its Articles of Association and corporate governance rules, which requires approval from the shareholders' meeting [1][4] - The company completed a share repurchase plan, repurchasing 5,087,505 shares and subsequently canceling 837,553 shares, reducing its registered capital from 550.437553 million to 549.6 million yuan [1][2] - The board of directors will increase its members from 7 to 8 by adding one non-independent director while maintaining the number of employee representative and independent directors [3] Group 2 - The company appointed Zhang Huasheng as a non-independent director and as the new Vice General Manager and Chief Financial Officer, effective upon approval at the upcoming shareholders' meeting [6][8] - Yang Yongguang resigned as Chief Financial Officer but will continue to serve as a director and Deputy General Manager [7] Group 3 - The company expects to engage in daily related party transactions totaling 2.651 billion yuan for the year 2026, which have been approved by the board and require shareholder approval [14][15] - The related party transactions are based on normal business operations and market pricing, ensuring no significant dependence on related parties [14][24] Group 4 - The company will hold its first extraordinary shareholders' meeting on February 4, 2026, to discuss the proposed amendments and appointments [26][27] - The meeting will allow for both on-site and online voting, with specific procedures outlined for participation [27][33]

Shareholding Situation - Prior to the implementation of the share reduction plan, certain directors and senior management of SANY Renewable Energy Co., Ltd. held shares as follows: Li Qiang held 2,965,500 shares, Zhou Fugui held 2,965,500 shares, Yu Liangwei held 780,000 shares, Yang Huaiyu held 125,000 shares, Chen Xiuqiang held 54,000 shares, and Liao Xudong held 315,000 shares [1] Reduction Plan Implementation Results - As of January 16, 2026, the share reduction plan was completed. Li Qiang reduced his holdings by 2,520,675 shares (0.2055% of total shares), Zhou Fugui by 2,965,500 shares (0.2418%), Yu Liangwei by 530,000 shares (0.0432%), Yang Huaiyu by 63,000 shares (0.0051%), and Liao Xudong by 192,005 shares (0.0157%). Chen Xiuqiang did not reduce his holdings [2][3] Compliance and Execution - The reduction plan did not set a minimum reduction quantity or ratio. The plan was executed in accordance with relevant laws and regulations, and the actual reduction was consistent with the previously disclosed plan [4]

Group 1 - The company has approved a proposal to apply for the registration of publicly issued corporate bonds totaling up to RMB 2 billion [1] - The company received approval from the China Securities Regulatory Commission (CSRC) for the public issuance of technology innovation corporate bonds [2] - The company successfully issued the first phase of the corporate bonds with a total scale of RMB 800 million, a subscription multiple of 2.71 times, a term of 3 years, and a coupon rate of 1.98% [2]

Core Viewpoint - The announcement details the stock listing related to the equity incentive plan of Sino Medical Science Technology Co., Ltd., including the number of shares, listing date, and the decision-making process for the stock allocation [2][3][15]. Group 1: Stock Listing Details - The type of stock listing is for equity incentive shares, with a total of 1,904,000 shares to be listed [2]. - The listing date for the shares is set for January 22, 2026 [3][13]. - The shares are part of the 2022 restricted stock incentive plan, with the first allocation of the second vesting period recently completed [3][9]. Group 2: Decision-Making Process - The decision-making process for the stock allocation involved multiple meetings of the board and supervisory board, with independent directors providing clear consent [4][6][8]. - The company conducted a public notice period for the proposed incentive recipients, during which no objections were raised by employees [5][6]. Group 3: Stock Allocation and Impact - A total of 7 individuals will receive the allocated shares [12]. - The new shares will increase the total share capital from 416,048,000 to 417,952,000 shares, representing approximately 0.4576% of the total shares before the allocation [14][15]. - The allocation is not expected to have a significant impact on the company's recent financial status or operating results [15].